Targets › PDE9A
1 program from 1 company in 1 trial: 1 Phase 2; Hematology.
Specifically hydrolyzes the second messenger cGMP, which is a key regulator of many important physiological processes. Highly specific: compared to other members of the cyclic nucleotide phosphodiesterase family, has the highest affinity and selectivity for cGMP. Specifically regulates natriuretic-peptide-dependent cGMP signaling in heart, acting as a regulator of cardiac hypertrophy in myocytes and muscle. (UniProt, O76083)
Open in Phaseline: the race on PDE9A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Imara | Tovinontrine (IMR-687) Phosphodiesterase 9A inhibitor | PDE9A | Phase 2 | Sickle Cell Disease | – |
Sickle Cell Disease (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.